Sugi Predict

Sugi Predict / Compounds / Leptacline

Leptacline

Leptacline

SCHEMBL509769

C1CCC(CN2CCCCC2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRM5 P08912 2/20 1.00
▸ ADRA2C P18825 1/20 1.00
▸ ACHE P22303 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ CHRM2 P08172 1/20 0.50
▸ CHRM4 P08173 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ CASP1 P29466 1/20 0.49
▸ CASP4 P49662 1/20 0.49
▸ CASP5 P51878 1/20 0.49
▸ OPRM1 P35372 3/20 0.44
▸ OPRL1 P41146 3/20 0.44
▸ OPRD1 P41143 1/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ HRH3 Q9Y5N1 2/20 0.43
▸ SIGMAR1 Q99720 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515104 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL20643257 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL18616997 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL30340995 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL3439882 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL18361231 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL19575409 1.00 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL1827882 0.97 CHRM5 (0.94) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL3439903 0.94 CHRM5 (0.90) CHRM5ADRA2CACHESMN1; SMN2CHRM2
SCHEMBL3611455 0.94 CHRM5 (0.90) CHRM5ADRA2CACHESMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 — — US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
WO-2026107076-A1 CDK2 INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2026-05-21 — — WO disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 — — US disclosed
US-20230321067-A1 DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2023-10-12 — — US disclosed
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS NOVARTIS AG (CH) 2023-06-08 — — US disclosed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 — — US disclosed
EP-0828737-A1 ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-03-18 — — EP disclosed
EP-0821674-A1 CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1998-02-04 — — EP disclosed
WO-1996033175-A1 CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1996-10-24 — — WO disclosed
US-4069256-A Anti-inflammatory phenyl-lower-alkylamines STERLING DRUG INC. (US) 1978-01-17 — — US disclosed
US-4028366-A ANTIINFLAMMATORY AGENTS STERLING DRUG INC. (US) 1977-06-07 — — US disclosed
US-3947458-A RHODIUM CATALYST, REACTING NITROGEN COMPOUND, OLEFIN, CARBON MONOXIDE, WATER MONSANTO COMPANY (US) 1976-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN CHRM5 4367/4885ADRA2C 4410/4885ACHE 3025/4885
US-20230321067-A1 DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 CHRM5 4669/4885ADRA2C 3209/4885ACHE 4430/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885
US-20230174933-A1 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS HAVCR2, MICA, CD74 CHRM5 4353/4885ADRA2C 4048/4885ACHE 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.